Anneke I. den Hollander

Anneke I. den Hollander

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
SVSanne K. Verbakel
Sanne K. Verbakel
RHRamon A.C. van Huet
Ramon A.C. van Huet
CBCamiel Boon
Camiel Boon
AHAnneke I. den Hollander
Anneke I. den Hollander
RCRob W.J. Collin
Rob W.J. Collin
BKB. Jeroen Klevering
B. Jeroen Klevering
Retinitis pigmentosa (RP) encompasses a group of inherited retinal dystrophies characterized by the primary degeneration of rod and cone photoreceptors. RP is a leading cause of visual disability, with a worldwide prevalence of 1:4000. Although the majority of RP cases are non-syndromic, 20-30% of patients with RP also have an associated non-ocular condition. RP typically manifests with night blindness in adolescence, followed by concentric visual field loss, reflecting the principal dysfunction of rod photoreceptors; central vision loss occurs later in life due to cone dysfunction. Photoreceptor function measured with an electroretinogram is markedly reduced or even absent. Optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging show a progressive loss of outer retinal layers and altered lipofuscin distribution in a characteristic pattern. Over the past three decades, a vast number of disease-causing variants in more than 80 genes have been associated with non-syndromic RP. The wide heterogeneity of RP makes it challenging to describe the clinical findings and pathogenesis. In this review, we provide a comprehensive overview of the clinical characteristics of RP specific to genetically defined patient subsets. We supply a unique atlas with color fundus photographs of most RP subtypes, and we discuss the relevant considerations with respect to differential diagnoses. In addition, we discuss the genes involved in the pathogenesis of RP, as well as the retinal processes that are affected by pathogenic mutations in these genes. Finally, we review management strategies for patients with RP, including counseling, visual rehabilitation, and current and emerging therapeutic options.

25 February 2020 in Ophthalmic and Physiological Optics
Verified
Journal Article
Open access
THThomas J Heesterbeek
Thomas J Heesterbeek
LLLaura Lorés‐Motta
Laura Lorés‐Motta
CHCarel B Hoyng
Carel B Hoyng
YLYara T E Lechanteur
Yara T E Lechanteur
AHAnneke I. den Hollander
Anneke I. den Hollander
Purpose: Age‐related macular degeneration (AMD) is a degenerative disease of the macula, often leading to progressive vision loss. The rate of disease progression can vary among individuals and has been associated with multiple risk factors. In this review, we provide an overview of the current literature investigating phenotypic, demographic, environmental, genetic, and molecular risk factors, and propose the most consistently identified risk factors for disease progression in AMD based on these studies. Finally, we describe the potential use of these risk factors for personalised healthcare. Recent findings: While phenotypic risk factors such as drusen and pigment abnormalities become more important to predict disease progression during the course of the disease, demographic, environmental, genetic and molecular risk factors are more valuable at earlier disease stages. Demographic and environmental risk factors such as age and smoking are consistently reported to be related to disease progression, while other factors such as sex, body mass index (BMI) and education are less often associated. Of all known AMD variants, variants that are most consistently reported with disease progression are rs10922109 and rs570618 in CFH , rs116503776 in C2/CFB/SKIV2L , rs3750846 in ARMS2/HTRA1 and rs2230199 in C3 . However, it seems likely that other AMD variants also contribute to disease progression but to a lesser extent. Rare variants have probably a large effect on disease progression in highly affected families. Furthermore, current prediction models do not include molecular risk factors, while these factors can be measured accurately in the blood. Possible promising molecular risk factors are High‐Density Lipoprotein Cholesterol (HDL‐C), Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), zeaxanthin and lutein. Summary: Phenotypic, demographic, environmental, genetic and molecular risk factors can be combined in prediction models to predict disease progression, but the selection of the proper risk factors for personalised risk prediction will differ among individuals and is dependent on their current disease stage. Future prediction models should include a wider set of genetic variants to determine the genetic risk more accurately, and rare variants should be taken into account in highly affected families. In addition, adding molecular factors in prediction models may lead to preventive strategies and personalised advice.

6 March 2024 in Nature
Verified
Journal Article
Open access
PDF file
MKMinna K. Karjalainen
Minna K. Karjalainen
SKSavita Karthikeyan
Savita Karthikeyan
COClare Oliver-Williams
Clare Oliver-Williams
ESEeva Sliz
Eeva Sliz
EAElias Allara
Elias Allara
JKJohannes Kettunen
Johannes Kettunen
Genome-wide association analyses using high-throughput metabolomics platforms have led to novel insights into the biology of human metabolism1–7. This detailed knowledge of the genetic determinants of systemic metabolism has been pivotal for uncovering how genetic pathways influence biological mechanisms and complex diseases8–11. Here we present a genome-wide association study for 233 circulating metabolic traits quantified by nuclear magnetic resonance spectroscopy in up to 136,016 participants from 33 cohorts. We identify more than 400 independent loci and assign probable causal genes at two-thirds of these using manual curation of plausible biological candidates. We highlight the importance of sample and participant characteristics that can have significant effects on genetic associations. We use detailed metabolic profiling of lipoprotein- and lipid-associated variants to better characterize how known lipid loci and novel loci affect lipoprotein metabolism at a granular level. We demonstrate the translational utility of comprehensively phenotyped molecular data, characterizing the metabolic associations of intrahepatic cholestasis of pregnancy. Finally, we observe substantial genetic pleiotropy for multiple metabolic pathways and illustrate the importance of careful instrument selection in Mendelian randomization analysis, revealing a putative causal relationship between acetone and hypertension. Our publicly available results provide a foundational resource for the community to examine the role of metabolism across diverse diseases.

1 November 2018 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
ELElisabeth M. van Leeuwen
Elisabeth M. van Leeuwen
EEEszter Emri
Eszter Emri
BMBénédicte MJ Merle
Bénédicte MJ Merle
JCJohanna M. Colijn
Johanna M. Colijn
EKEveline Kersten
Eveline Kersten
Imre LengyelImre Lengyel
Imre Lengyel
There is an urgency to find new treatment strategies that could prevent or delay the onset or progression of AMD. Different classes of lipids and lipoproteins metabolism genes have been associated with AMD in a multiple ways, but despite the ever-increasing knowledge base, we still do not understand fully how circulating lipids or local lipid metabolism contribute to AMD. It is essential to clarify whether dietary lipids, systemic or local lipoprotein metabolismtrafficking of lipids in the retina should be targeted in the disease. In this article, we critically evaluate what has been reported in the literature and identify new directions needed to bring about a significant advance in our understanding of the role for lipids in AMD. This may help to develop potential new treatment strategies through targeting the lipid homeostasis.

1 April 2017 in Molecular Immunology
Verified
Journal Article
Open access
MGMaartje J. Geerlings
Maartje J. Geerlings
EJEiko K. de Jong
Eiko K. de Jong
AHAnneke I. den Hollander
Anneke I. den Hollander
Age-related macular degeneration (AMD) is a progressive retinal disease and the major cause of irreversible vision loss in the elderly. Numerous studies have found both common and rare genetic variants in the complement pathway to play a role in the pathogenesis of AMD. In this review we provide an overview of rare variants identified in AMD patients, and summarize the functional consequences of rare genetic variation in complement genes on the complement system. Finally, we discuss the relevance of this work in light of ongoing clinical trials that study the effectiveness of complement inhibitors against AMD.

1 March 2014 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
NSNicole T.M. Saksens
Nicole T.M. Saksens
MFMonika Fleckenstein
Monika Fleckenstein
SSSteffen Schmitz-Valckenberg
Steffen Schmitz-Valckenberg
FHFrank G. Holz
Frank G. Holz
AHAnneke I. den Hollander
Anneke I. den Hollander
CHCarel B. Hoyng
Carel B. Hoyng